aspirin standard release/dipyridamole modified release / Generic mfg. - LARVOL DELTA

Updated Assessment of Practice Patterns of Perioperative Management of Antiplatelet and Anticoagulant Therapy in Interventional Pain Management. (PubMed, Pain Physician) - "The results in the 2021 survey illustrate a continued pattern of discontinuing antiplatelet and anticoagulant therapy in the perioperative period. The majority of discontinuation patterns appear to fall within guidelines."

Journal • Cardiovascular • CNS Disorders • Pain

Aspirin-Dipyridamole in Fluctuating Small Vessel Disease Ischemic Strokes (AAN 2023) - "Background Aggrenox is a fixed-dose combination of aspirin, an antiplatelet, and extended-release dipyridamole, which acts both to impair platelet function and cause vasodilation. Conclusions Data in the Aggrenox population shows a trend toward improvement in NIHSS throughout hospitalization. Once control group data is collected, comparative statistics will be used to analyze outcomes between the two groups."

Cardiovascular • Ischemic stroke

A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. (PubMed, PLoS One) - "In this study of hospitalized patients with COVID-19, while the outcomes of COVID illness severity, odds of mortality, and chance of respiratory failure were better in the Aggrenox group compared to standard of care alone, the data did not reach statistical significance to support the standard use of adjuvant Aggrenox in such patients."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ATTAC-19: Aggrenox To Treat Acute Covid-19 (clinicaltrials.gov) - P3 | N=99 | Completed | Sponsor: Rutgers, The State University of New Jersey | Recruiting ➔ Completed | Trial primary completion date: Mar 2021 ➔ Oct 2021

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

"but Aggrenox has increased ICH), or are there no great options? 3/" (@orion7710)

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P=N/A; N=18; Terminated; Sponsor: Oklahoma Medical Research Foundation; Completed ➔ Terminated; Slow recruitment

Trial termination • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

ATTAC-19: Aggrenox To Treat Acute Covid-19 (clinicaltrials.gov) - P3; N=132; Recruiting; Sponsor: Rutgers, The State University of New Jersey; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

ATTAC-19: Aggrenox To Treat Acute Covid-19 (clinicaltrials.gov) - P3; N=132; Not yet recruiting; Sponsor: Rutgers, The State University of New Jersey; Trial primary completion date: Dec 2020 ➔ Mar 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

"Aggrenox" (@csentropy)

[VIRTUAL] Characterization and Antithrombotic Treatment of Patients with Acute Ischemic Stroke and No Atrial Fibrillation: A Real-world Study (ISTH 2020) - "Demographics and comorbidities in 6 months prior to hospitalization and treatment with antiplatelets (P2Y12 inhibitors [P2Y12i] and aggrenox) and anticoagulants (warfarin and direct oral anticoagulants [DOACs]) in 30 days after hospitalization were examined. Use of over-the-counter aspirin and in-hospital drug exposure were not captured in these databases... The large majority of patients do not receive P2Y12i, aggrenox, or anticoagulant treatment within 30 days after AIS. Among those treated, use of P2Y12i is the most common initial treatment. Future studies may evaluate outcomes associated with these treatments."

Clinical • Real-World Evidence • Atrial Fibrillation • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Immunology • Ischemic stroke • Metabolic Disorders • Peripheral Arterial Disease • Reperfusion Injury

ATTAC-19: Aggrenox To Treat Acute Covid-19 (clinicaltrials.gov) - P3; N=132; Not yet recruiting; Sponsor: Rutgers, The State University of New Jersey

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease

HLX 06-03: GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients (clinicaltrials.gov) - P=N/A; N=664; Completed; Sponsor: W.L.Gore & Associates; Active, not recruiting ➔ Completed; Trial completion date: Feb 2020 ➔ May 2020

Clinical • Trial completion • Trial completion date • Cardiovascular • Reperfusion Injury • MRI

Preventing Arteriovenous Shunt Failure in Hemodialysis Patients: A Population-Based Cohort Study. (PubMed, J Thromb Haemost) - "Antiplatelet agents but not wafarin might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals since it might increase the rate of intracerebral hemorrhage."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Nephrology • Renal Disease • Thrombosis

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P=N/A; N=18; Completed; Sponsor: Oklahoma Medical Research Foundation; Recruiting ➔ Completed; N=50 ➔ 18

Enrollment change • Trial completion

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Boehringer Ingelheim

New P1 trial

Glenmark Pharmaceuticals receives ANDA approval for aspirin and extended-release dipyridamole capsules, 25 mg/200 mg (Glenmark Press Release) - "Glenmark Pharmaceuticals Inc., USA...has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc."

ANDA

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines. (PubMed, Pain Physician) - "Based on the survey of current literature, and published clinical guidelines, recommendations for patients presenting with ongoing antithrombotic therapy prior to interventional techniques are variable, and are based on comprehensive analysis of each patient and the risk-benefit analysis of intervention."

Clinical • Journal